Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

PARIS--(BUSINESS WIRE)--Dec 17, 2021--

Related Keywords

France ,Saclay ,France General ,Taiwan ,Shanghai ,China ,United States ,Paris ,Hong Kong ,Cambridge ,Cambridgeshire ,United Kingdom ,Macau ,American ,Fanny Allaire ,Pascal Prigent ,Jess Smith ,David Loew ,Ipsen Euronext ,Stephanie Boyer ,Global Communications ,European Commission ,Uncertainties Of The Company ,Drug Administration ,Terns Pharmaceuticals ,Nasdaq ,Exchange Commission ,Head Of Global Communications ,European Medicines Agency ,Business Development ,Euronext ,Primary Biliary Cholangitis ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Chief Executive Officer ,Breakthrough Therapy ,Rare Disease ,Consumer Healthcare ,Total Sales ,Sponsored Leveli American Depositary Receipt ,Chronic Liver Failure ,Nasdaq Global Select Market ,French Autorit ,Des March ,Private Securities Litigation Reform Act ,Registration Document ,Transplantation Hepatology ,Business Wire ,Covid19 ,Coronavirus ,Covid 19 ,Ontracts And Orders ,Licensing Agreements ,Iagnosis And Treatment ,Medication ,Medical Research ,Clinical Trials ,Product Testing ,Drug Trials ,Overnment And Politics ,Overnment Regulations ,Drug Approvals ,Intellectual Property ,Patents ,Liver Disease ,Cirrhosis ,New Product Development ,Harmaceutical Manufacturing ,Ealth Care Industry ,Medical Biotechnology Industry ,Sec Filings ,Product Approvals ,Technology ,Ung Disease ,Health ,Iseases And Conditions ,Infectious Diseases ,Business ,Corporate News ,Products And Services ,New Products And Services ,